# Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients

Study · id `cardio:ct-nct05070494` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05070494](<https://clinicaltrials.gov/study/NCT05070494>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05070494

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 175 participants.

## Technical summary

Registry record NCT05070494. Randomized; double masking; primary purpose treatment. Start 2021-03-01 (actual); primary completion 2022-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 175 participants (planned count; ClinicalTrials.gov record NCT05070494, source copy `cardio:ctgov-nct05070494-2021-11-03`, retrieved 2026-10-26)
- Started: 2021-03-01 (actual) (ClinicalTrials.gov record NCT05070494, source copy `cardio:ctgov-nct05070494-2021-11-03`, retrieved 2026-10-26)
- Primary completion: 2022-04-01 (anticipated) (ClinicalTrials.gov record NCT05070494, source copy `cardio:ctgov-nct05070494-2021-11-03`, retrieved 2026-10-26)
- Completion: 2022-12-01 (anticipated) (ClinicalTrials.gov record NCT05070494, source copy `cardio:ctgov-nct05070494-2021-11-03`, retrieved 2026-10-26)
- Countries: Thailand (ClinicalTrials.gov record NCT05070494, source copy `cardio:ctgov-nct05070494-2021-11-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05070494-2021-11-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients
- Acronym: Enhance
- Condition: ESRD
- Condition: Influenza Vaccine
- Condition: Seroprotection
- Intervention (Biological): Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)
- Lead sponsor: Mahidol University
- Lead sponsor class: OTHER
- Collaborator: Bhumirajanagarindra Kidney Institute, Thailand
- Collaborator class: OTHER
- Collaborator: Ministry of Health, Thailand
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Mahidol University (`cardio:org-mahidol-university`)

## Provenance

Content hash: 9697065096fc469ca5fb9a2a93becde31daa1cd4cbab1332f30b8f9b90854151
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
